Aptevo Therapeutics (NASDAQ:APVO) announced its earnings results on Thursday. The biotechnology company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.07, MarketWatch Earnings reports. The company had revenue of $6.83 million for the quarter, compared to analysts’ expectations of $4.17 million.
Aptevo Therapeutics traded up $0.46, hitting $4.96, during trading hours on Friday, MarketBeat.com reports. 4,855 shares of the company’s stock traded hands, compared to its average volume of 119,438. The firm has a market capitalization of $101.86 million, a price-to-earnings ratio of -2.94 and a beta of 0.21. Aptevo Therapeutics has a twelve month low of $1.15 and a twelve month high of $6.35. The company has a current ratio of 4.47, a quick ratio of 4.39 and a debt-to-equity ratio of 0.20.
Several equities research analysts have recently commented on APVO shares. ValuEngine raised Aptevo Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, June 1st. Zacks Investment Research raised Aptevo Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 24th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and set a $11.00 target price on shares of Aptevo Therapeutics in a report on Friday.
Aptevo Therapeutics Inc, a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn.
Recommended Story: Penny Stocks, Risk and Reward Factors
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.